Potential therapeutic role of melatonin on STZ-induced diabetic central neuropathy: A biochemical, histopathological, immunohistochemical and ultrastructural study

Metwally, Mohamed M.M.; Ebraheim, Lamiaa L.M.; Galal, Azza A.A.

doi:10.1016/j.acthis.2018.09.008

Cited by 46 publications

(27 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the sciatic nerves, melatonin has been reported to reduce vacuolization of the myelin sheath, axon-myelin separation and the number of degenerated fibers. In cerebral cortices, melatonin-treated diabetic rats showed the reduction in the neurodegenerative and necrotic changes; spongiosis and reactive astrogliosis were absent and scattered pyknotic neurons with perineural vacuolations and swollen neurons with karolysis were remarkably reduced in animals with cerebral diabetic neuropathy [156,157].…”

Section: Therapeutic Potentials Of Melatonin For Diabetic Neuropathymentioning

confidence: 95%

Melatonin: new insights on its therapeutic properties in diabetic complications

Pourhanifeh

Hosseinzadeh

Dehdashtian

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Diabetes and diabetic complications are considered as leading causes of both morbidity and mortality in the world. Unfortunately, routine medical treatments used for affected patients possess undesirable side effects, including kidney and liver damages as well as gastrointestinal adverse reactions. Therefore, exploring the novel therapeutic strategies for diabetic patients is a crucial issue. It has been recently shown that melatonin, as main product of the pineal gland, despite its various pharmacological features including anticancer, anti-aging, antioxidant and antiinflammatory effects, exerts anti-diabetic properties through regulating various cellular mechanisms. The aim of the present review is to describe potential roles of melatonin in the treatment of diabetes and its complications.

show abstract

Section: Therapeutic Potentials Of Melatonin For Diabetic Neuropathymentioning

confidence: 95%

Melatonin: new insights on its therapeutic properties in diabetic complications

Pourhanifeh

Hosseinzadeh

Dehdashtian

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…The individual score for each animal was determined and then the median score for each group was calculated for various histopathological lesions. 27) Quantification of cell density in various hippocampal subdivisions; cornu ammonis (CA) 1-3 subfields, and dentate gyrus (DG), was performed using a computerized microscopic image analyzer attached to full HD microscopic camera (Leica microsystems, Germany). We calculated the cell density at 40x objective magnification per unit area of the microscopic field (18.8913 mm 2 ).…”

Section: Biological and Pharmaceutical Bulletin Advance Publicationmentioning

confidence: 99%

Targeting the Oxytocin System to Ameliorate Early Life Depressive-Like Behaviors in Maternally-Separated Rats

Abdelwahab

Galal

El-Rahman

et al. 2021

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Oxytocin (OXT) -"the love hormone"has been involved in the anti-depressant activity of some selective serotonin reuptake inhibitors (SSRIs). The exact mechanism underlying the OXT pathway in depression is not fully clear. This study aimed to investigate the effect of OXT analogue, carbetocin (CBT) and the SSRI, escitalopram (ESCIT) on depressive-like behaviors following maternal separation (MS). It is worthy to mention that intranasal CBT has been approved by FDA for Prader-Willi syndrome. Adolescent Wistar albino maternally-separated rats were given CBT, (100 μg/animal/day via inhalation route), and, ESCIT, (20 mg kg -1 , po) either alone or in combination for 7 days. Repeated 3-h MS demonstrated increased immobility time in forced swim test (FST) and decreased locomotor activity in open field test. MS elevated plasma level of adrenocortico-trophic hormone (ACTH) but notably reduced plasma OXT, with no effect on hippocampal OXT-R expression. Following MS, hippocampal contents of 5hydroxytryptamine receptors (5HT1A-R), serotonin transporter (SERT) were increased. CBT and ESCIT corrected the behavioral dysfunction in FST and suppressed the high levels of ACTH. Additionally, both treatments boosted OXT level, reduced 5HT1A-R and normalized SERT contents, which reflects increased availability of serotonin. Finally, CBT markedly ameliorated the histopathological damage induced by MS and suppressed the increased glial fibrillary acidic protein. CBT and ESCIT manage depressive-like behavior by positively affecting serotonergic and oxytocinergic systems. Targeting OXT system -using CBT-ameliorated depressive like behaviors induced by maternal separation most probably via enhancing OXT plasma levels, attenuating hormonal ACTH and restoring the expression of hippocampal oxytocin and serotonin mechanisms.

show abstract

“…It has been reported that DM causes an increase in oxidative stress by measuring different markers, such as increased malondialdehyde (MDA), lipid peroxidation, and reduced levels of glutathione-S-transferase (GSH), superoxide dismutase (SOD), and catalase. MEL has been shown to reverse the change in the levels of all of these markers, in addition to increasing the total antioxidant capacity (TAC) [ 29 , 30 , 31 , 32 , 33 ].…”

Section: Diabetic Neuropathy and Retinopathymentioning

confidence: 99%

“…Metwally et al [ 33 ] investigated the effect of MEL (50 mg/kg, i.p.) on central neuropathy caused by STZ-induced DM in Wistar rats.…”

Section: Diabetic Neuropathy and Retinopathymentioning

confidence: 99%

Effects of Melatonin on Diabetic Neuropathy and Retinopathy

Oliveira-Abreu

Cipolla‐Neto

Leal‐Cardoso

2021

IJMS

View full text Add to dashboard Cite

Diabetes mellitus (DM) leads to complications, the majority of which are nephropathy, retinopathy, and neuropathy. Redox imbalance and inflammation are important components of the pathophysiology of these complications. Many studies have been conducted to find a specific treatment for these neural complications, and some of them have investigated the therapeutic potential of melatonin (MEL), an anti-inflammatory agent and powerful antioxidant. In the present article, we review studies published over the past 21 years on the therapeutic efficacy of MEL in the treatment of DM-induced neural complications. Reports suggest that there is a real prospect of using MEL as an adjuvant treatment for hypoglycemic agents. However, analysis shows that there is a wide range of approaches regarding the doses used, duration of treatment, and treatment times in relation to the temporal course of DM. This wide range hinders an objective analysis of advances and prospective vision of the paths to be followed for the unequivocal establishment of parameters to be used in an eventual therapeutic validation of MEL in neural complications of DM.

show abstract

Potential therapeutic role of melatonin on STZ-induced diabetic central neuropathy: A biochemical, histopathological, immunohistochemical and ultrastructural study

Cited by 46 publications

References 100 publications

Melatonin: new insights on its therapeutic properties in diabetic complications

Melatonin: new insights on its therapeutic properties in diabetic complications

Targeting the Oxytocin System to Ameliorate Early Life Depressive-Like Behaviors in Maternally-Separated Rats

Effects of Melatonin on Diabetic Neuropathy and Retinopathy

Contact Info

Product

Resources

About